SciSparc Ltd. (SPRC) has released an update.
SciSparc Ltd., a pharmaceutical firm specializing in central nervous system disorders, has announced the submission of an IND application to the FDA for a Phase IIb trial of SCI-110, aimed at treating Tourette Syndrome. The international trial will take place at prestigious institutions in the US, Germany, and Israel, focusing on the drug’s efficacy, safety, and tolerability in adults. SciSparc believes that their proprietary drug, which includes components like dronabinol and palmitoylethanolamide, could significantly improve treatment for TS.
For further insights into SPRC stock, check out TipRanks’ Stock Analysis page.
